AlloVir, Inc. (NASDAQ:ALVR) Short Interest Down 14.0% in January

AlloVir, Inc. (NASDAQ:ALVR) was the target of a large drop in short interest in January. As of January 31st, there was short interest totalling 59,500 shares, a drop of 14.0% from the January 15th total of 69,200 shares. Currently, 2.6% of the company’s stock are short sold. Based on an average trading volume of 26,100 shares, the days-to-cover ratio is presently 2.3 days.

AlloVir Stock Performance

Shares of NASDAQ ALVR opened at $9.90 on Tuesday. AlloVir has a fifty-two week low of $7.96 and a fifty-two week high of $24.15. The stock has a market cap of $49.80 million, a price-to-earnings ratio of -0.49 and a beta of 0.65. The firm’s 50-day simple moving average is $10.06 and its 200 day simple moving average is $14.50.

Hedge Funds Weigh In On AlloVir

Large investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new position in AlloVir in the 4th quarter valued at about $25,000. BNP Paribas Financial Markets bought a new position in shares of AlloVir during the 4th quarter worth approximately $31,000. Jane Street Group LLC lifted its position in shares of AlloVir by 47.8% during the 4th quarter. Jane Street Group LLC now owns 123,159 shares of the company’s stock worth $52,000 after buying an additional 39,808 shares in the last quarter. Northern Trust Corp lifted its position in shares of AlloVir by 0.8% during the 4th quarter. Northern Trust Corp now owns 159,685 shares of the company’s stock worth $67,000 after buying an additional 1,267 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of AlloVir during the 4th quarter worth approximately $142,000. Institutional investors own 66.05% of the company’s stock.

AlloVir Company Profile

AlloVir, Inc engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.